Replies to post #200 on Evolus (EOLS)

[DewDiligence]

EOLS pre-announces 4Q22 Jeuveau sales=$43.6M, +26%YoY:

https://www.businesswire.com/news/home/20230118005311/en

Full-year 2022 Jeuveau sales were $149M. Cash at 12/31/22 was $53.4M, down from $65.6M at 9/30/22 (#msg-170403381).

EOLS issued 2023 sales guidance of $180-190M (+24% YoY at the midpoint of the range) and also announced an “aspirational” goal of $500M in annual sales by 2028. Further, EOLS said its expects non-GAAP profitability in 4Q23.

EOLS plans to announce preliminary data from the phase-2 "double dose" trial on 1/28/23.